Gyre Therapeutics (GYRE) Earnings Call Presentation

Developing Anti-Fibrotic Therapeutics for Chronic Organ Diseases Corporate Presentation April 2025 This presentation concerns a discussion of investigational drugs that are under preclinical and/or clinical investigation and which have not yet been approved for marketing by the U.S. Food and Drug Administration. They are currently limited by Federal law to investigational use, and no representations are made as to their safety or effectiveness for the purposes for which they are being investigated. 2 Gyre T ...